X4 Pharmaceuticals (XFOR) Total Liabilities (2018 - 2025)
X4 Pharmaceuticals (XFOR) has disclosed Total Liabilities for 8 consecutive years, with $101.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Total Liabilities fell 14.01% year-over-year to $101.9 million, compared with a TTM value of $101.9 million through Sep 2025, down 14.01%, and an annual FY2024 reading of $124.3 million, up 29.26% over the prior year.
- Total Liabilities was $101.9 million for Q3 2025 at X4 Pharmaceuticals, up from $101.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $124.3 million in Q4 2024 and bottomed at $49.9 million in Q1 2022.
- Average Total Liabilities over 5 years is $84.6 million, with a median of $96.2 million recorded in 2023.
- The sharpest move saw Total Liabilities soared 107.8% in 2023, then dropped 14.01% in 2025.
- Year by year, Total Liabilities stood at $52.8 million in 2021, then soared by 54.53% to $81.5 million in 2022, then rose by 17.94% to $96.2 million in 2023, then rose by 29.26% to $124.3 million in 2024, then dropped by 17.99% to $101.9 million in 2025.
- Business Quant data shows Total Liabilities for XFOR at $101.9 million in Q3 2025, $101.2 million in Q2 2025, and $107.1 million in Q1 2025.